Morbidity and Mortality with Pericardial Effusion Associated with Direct Oral Anticoagulants and P-glycoprotein Inhibitors
Article Sidebar
Main Article Content
Abstract
Pericardial effusion is a rare but potentially fatal adverse effect reported with apixaban, dabigatran, edoxaban, and rivaroxaban (direct oral anticoagulants). We report three cases of pericardial effusion that occurred at a single institution with two patients requiring urgent pericardiocentesis. All patients took a direct oral anticoagulant with a p-glycoprotein inhibitor or a combined p-glycoprotein and CYP3A4 inhibitor. Our patients had underlying conditions predisposing them to developing pericardial effusion.
Article Details
Copyright (c) 2025 Song J, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Jessica Song, Thomas J. Long School of Pharmacy, University of the Pacific
Jessica Song, PharmD
Jered Arquiette, San Joaquin General Hospital
Jered Arquiette, PharmD
Jack Vo, Thomas J. Long School of Pharmacy, University of the Pacific
Jack Vo, PharmD
Benjamin Dang, Thomas J. Long School of Pharmacy, University of the Pacific
Benjamin Dang, PharmD Candidate
Susie Bae, Thomas J. Long School of Pharmacy, University of the Pacific
Susie Bae, PharmD Candidate
1. Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149:e1–e156. Available from: https://doi.org/10.1161/cir.0000000000001193
2. Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing GJ, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160:e545–e608. Available from: https://doi.org/10.1016/j.chest.2021.07.055
3. Apixaban (Eliquis) prescribing information. Princeton (NJ): Bristol-Myers Squibb Company and New York (NY): Pfizer Inc.; 2025.
4. Dabigatran etexilate (Pradaxa) prescribing information. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals, Inc.; 2023.
5. Edoxaban (Savaysa) prescribing information. Basking Ridge (NJ): Daiichi Sankyo, Inc.; 2024.
6. Rivaroxaban (Xarelto) prescribing information. Titusville (NJ): Janssen Pharmaceuticals, Inc.; 2025 Apr.
7. Dy EA, Shiltz DL. Hemopericardium and cardiac tamponade associated with dabigatran use. Ann Pharmacother. 2012;46:e18. Available from: https://doi.org/10.1345/aph.1r112
8. Sheikh AB, Shah I, Sagheer S, Javed N, Minhas AMK, Lopez ED, et al. Hemopericardium in the setting of direct oral anticoagulant use: an updated systematic review. Cardiovasc Revasc Med. 2022;39:73–83. Available from: https://doi.org/10.1016/j.carrev.2021.09.010
9. Barton CA, McMillian WD, Raza SS, Keller RE. Hemopericardium in a patient treated with dabigatran etexilate. Pharmacotherapy. 2012;32(5):e103–7. Available from: https://doi.org/10.1002/j.1875-9114.2012.01036.x
10. Kızılırmak F, Gunes HM, Guler E, Demir GG, Karaca O, Canpolat HG. Hemopericardium and cardiac tamponade in a patient treated with dabigatran etexilate. Korean Circ J. 2016;46(1):99–101. Available from: https://doi.org/10.4070/kcj.2016.46.1.99
11. Jelani QU, Gordon R, Schussheim A. Dabigatran-induced spontaneous hemopericardium and cardiac tamponade. Tex Heart Inst J. 2017;44(5):370–2. Available from: https://doi.org/10.14503/thij-16-6073
12. Song S, Cook J, Goulbourne C, Meade M, Salciccioli L, Lazar J. First reported case of hemopericardium related to dabigatran use reversed by new antidote idarucizumab. Case Rep Cardiol. 2017;2017:6458636. Available from: https://doi.org/10.1155/2017/6458636
13. Yu JH, Liu HH, Hsieh MJ, Hsieh IC, Chu PH, Chen DY. Spontaneous bilateral haemothorax with haemopericardium secondary to rivaroxaban. J Clin Pharm Ther. 2020;45(5):1175–8. Available from: https://doi.org/10.1111/jcpt.13116
14. Shivamurthy P, Brar N, Therrien ML. Isolated hemopericardium associated with rivaroxaban: first case report. Pharmacotherapy. 2014;34(9):e169–72. Available from: https://doi.org/10.1002/phar.1474
15. Mehta A, Burkland D, Mathuria N. Isolated hemopericardium after initiation of rivaroxaban: implications and potential mechanisms. Clin Pract. 2019;9(1):1096. Available from: https://doi.org/10.4081/cp.2019.1096
16. Shastri P, Bhuta S, Oostra C, Monroe T. Hemopericardium with subsequent cardiac tamponade secondary to rivaroxaban treatment: a case report. Eur Heart J Case Rep. 2020;5(1):ytaa482. Available from: https://doi.org/10.1093/ehjcr/ytaa482
17. Menendez D, Michel J. Hemopericardium with tamponade following rivaroxaban administration and its attenuation by CYP3A4 inhibitors. Proc (Bayl Univ Med Cent). 2016;29(4):414–5. Available from: https://doi.org/10.1080/08998280.2016.11929492
18. Basnet S, Tachamo N, Tharu B, Dhital R, Ghimire S, Poudel DR. Life-threatening hemopericardium associated with rivaroxaban. Case Rep Cardiol. 2017;2017:4691325. Available from: https://doi.org/10.1155/2017/4691325
19. Ioppolo AM, Longobardo L, D'Isa S, De Gregorio P, Manfredi M, De Cesare NB. An uncommon case of spontaneous hemopericardium in a patient treated with rivaroxaban. J Cardiovasc Echogr. 2019;29(4):180–2. Available from: https://doi.org/10.4103/jcecho.jcecho_57_19
20. Olagunju A, Khatib M, Palermo-Alvarado F. A possible drug-drug interaction between Eliquis and amiodarone resulting in hemopericardium. Cureus. 2021;13(2):e13486. Available from: https://doi.org/10.7759/cureus.13486
21. Cinelli M, Uddin A, Duka I, Soomro A, Tamburrino F, Ghavami F, Lafferty J. Spontaneous hemorrhagic pericardial and pleural effusion in a patient receiving apixaban. Cardiol Res. 2019;10(4):249–52. Available from: https://doi.org/10.14740/cr902
22. Sigawy C, Apter S, Vine J, Grossman E. Spontaneous hemopericardium in a patient receiving apixaban therapy: first case report. Pharmacotherapy. 2015;35(7):e115–7. Available from: https://doi.org/10.1002/phar.1602
23. Sablani N, Garg J, Hasan B, Patel R, Martinez MW. First reported case series in the United States of hemopericardium in patients on apixaban. HeartRhythm Case Rep. 2017;4(2):82–4. Available from: https://doi.org/10.1016/j.hrcr.2017.11.015
24. Tsai TY, Leu HB, Lo LW, Chen SA, Hsu PF. Spontaneous hemopericardium complicated with hemothorax in a patient receiving edoxaban therapy: a case report. Acta Cardiol Sin. 2019;35(3):342–4. Available from: https://doi.org/10.6515/acs.201905_35(3).20190212a
25. Tsai TY, Leu HB, Lo LW, Chen SA, Hsu PF. Spontaneous hemopericardium complicated with hemothorax in a patient receiving edoxaban therapy: a case report. Acta Cardiol Sin. 2019;35:342–4. Available from: https://doi.org/10.6515/acs.201905_35(3).20190212a
26. Bader FM, Hagan ME, Crompton JA, Gilbert EM. The effect of beta-blocker use on cyclosporine level in cardiac transplant recipients. J Heart Lung Transplant. 2005;24:2144–7. Available from: https://doi.org/10.1016/j.healun.2005.05.002
27. Souza FC, Neri JS, Marques EB, Barros RB, Scaramello CB. Should pharmacotherapy of digoxin be reviewed in male patients with heart failure in the case of association with carvedilol? Int J Cardiol. 2015;191:4–6. Available from: https://doi.org/10.1016/j.ijcard.2015.04.247
28. Chung H, Kim JM, Park JW, Noh J, Kim KA, Park JY. Effects of simvastatin on pharmacokinetics and anticoagulant effects of dabigatran in healthy subjects. Pharmaceuticals (Basel). 2023;16:364. Available from: https://doi.org/10.3390/ph16030364
29. Hindley B, Lip GYH, McCloskey AP, Penson PE. Pharmacokinetics and pharmacodynamics of direct oral anticoagulants. Expert Opin Drug Metab Toxicol. 2023;19:911–23. Available from: https://doi.org/10.1080/17425255.2023.2287472
30. Chahine J, Ala CK, Gentry JL, Pantalone KM, Klein AL. Pericardial diseases in patients with hypothyroidism. Heart. 2019;105:1027–33. Available from: https://doi.org/10.1136/heartjnl-2018-314528
31. Rehman KA, Betancor J, Xu B, Kumar A, Rivas CG, Sato K, et al. Uremic pericarditis, pericardial effusion, and constrictive pericarditis in end-stage renal disease: insights and pathophysiology. Clin Cardiol. 2017;40:839–46. Available from: https://doi.org/10.1002/clc.22770
32. Zhai G, Zhang B, Wang J, Liu Y, Zhou Y. Prognostic value of pericardial effusion size in patients with acute heart failure. Curr Vasc Pharmacol. 2022;20:508–16. Available from: https://doi.org/10.2174/1570161120666220721094739
33. Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol. 2000;40:91–8. Available from: https://doi.org/10.1177/00912700022008612
34. Lorenzo-Esteller L, Ramos-Polo R, Pons Riverola A, Pons Riverola A, Morillas H, Berdejo J, et al. Pericardial disease in patients with cancer: clinical insights on diagnosis and treatment. Cancers (Basel). 2024;16:1–14. Available from: https://doi.org/10.3390/cancers16203466
35. Frost CE, Byon W, Song Y, Wang J, Schuster AE, Boyd RA, et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol. 2015;79:838–46. Available from: https://doi.org/10.1111/bcp.12541